Target intelligence / Profile preview

Zika virus envelope glycoprotein (ZIKV E protein)

Target
ZIKV E protein
Molecular classification
Viral surface protein, Glycoprotein, Class II viral fusion protein
01

Overview

The Zika virus envelope (E) glycoprotein is the primary surface protein of the Zika virus (ZIKV) and a critical mediator of viral entry and pathogenesis. It is a class II viral fusion protein organized as a homodimer on the mature virion surface, consisting of three distinct ectodomains (DI, DII, and DIII) and a transmembrane anchor. The E protein facilitates the initial attachment of the virus to host cell receptors, such as DC-SIGN and GRP78, and mediates membrane fusion within the acidic environment of the endosome to release the viral genome into the cytoplasm. As the dominant target of the host's neutralizing humoral immune response, the E protein is the focal point for vaccine development and monoclonal antibody (mAb) therapies. Key epitopes, such as the fusion loop in DII and the lateral ridge in DIII, are targeted by potent neutralizing antibodies like ZIKV-117. However, a significant therapeutic challenge is antibody-dependent enhancement (ADE), where sub-neutralizing or cross-reactive antibodies from prior flavivirus infections can facilitate viral entry into Fc-receptor-bearing cells, potentially exacerbating disease. Consequently, drug and vaccine design must prioritize the induction of highly specific, strongly neutralizing antibodies to avoid these safety risks.

Other names
Zika virus E proteinZIKV EEnvelope proteinE proteinZika virus envelope glycoprotein epitopesZika virus surface glycoprotein
02

Mechanism of action

Neutralization of viral particles by blocking receptor binding sites, inhibition of pH-dependent conformational changes required for membrane fusion, and prevention of viral entry into host cells.

03

Biological functions

Viral attachmentReceptor bindingMembrane fusionViral entryClathrin-mediated endocytosis
04

Disease associations

Zika virus infectionCongenital Zika syndromeMicrocephalyGuillain-Barré syndrome
05

Safety considerations

Antibody-dependent enhancement (ADE)Cross-reactivity with Dengue virus (DENV)Potential for enhanced neurovirulence with specific mutationsRisk of fetal transmission if not fully neutralized
06

Interacting drugs

10 more in the full profile.

07

Biomarkers

Anti-ZIKV E IgM antibodiesAnti-ZIKV E IgG antibodiesZIKV RNAZIKV E protein glycosylation status

Beyond the preview

Go deeper on Zika virus envelope glycoprotein (ZIKV E protein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zika virus envelope glycoprotein (ZIKV E protein).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call